NASDAQ: LMRILumexa Imaging Holdings Inc Stock
$17.90-0.62 (-3.35%)
Updated Dec 16, 2025
LMRI Price
$17.90
Fair Value Price
-$10.86
Market Cap
N/A
52 Week Low
$17.15
52 Week High
$19.45
P/E
N/A
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
9.11
Operating Cash Flow
N/A
Beta
-1.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LMRI Overview
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. The company was founded in 2018 and is based in Raleigh, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LMRI's potential to beat the market
- LMRI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LMRI
RankedUnranked of 102
RankedUnranked of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.86 | A | |
| $28.95 | A | |
| $7.52 | A |
Be the first to know about important LMRI news, forecast changes, insider trades & much more!
LMRI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LMRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LMRI ($17.90) is overvalued by 264.81% relative to our estimate of its Fair Value price of -$10.86 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LMRI ($17.90) is not significantly undervalued (264.81%) relative to our estimate of its Fair Value price of -$10.86 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LMRI's short-term liabilities ($179.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more LMRI due diligence checks available for Premium users.
Valuation
LMRI fair value
Fair Value of LMRI stock based on Discounted Cash Flow (DCF)
Price
$17.90
Fair Value
-$10.86
Undervalued by
264.81%
LMRI ($17.90) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LMRI ($17.90) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LMRI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$1.7B
Liabilities
$1.5B
Debt to equity
9.11
LMRI's short-term liabilities ($179.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LMRI's long-term liabilities ($1.34B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LMRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
Lumexa Imaging Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.